Week in Review: Suzhou's Adagene Raises $8 Million for Antibody Discovery

Adagene, a Suzhou antibody company, closed an $8 million Series A round with participation by two Fidelity funds and the WuXi Venture Fund; Guangxi Wuzhou Pharma raised $3 million from Integra Holdings, a tech transfer company affiliated with the Hebrew University of Jerusalem; India's Cipla sold its 48% stake in API-maker Jiangsu Cdymax Pharma for $18.5 million; Hong Kong-based Luqa Pharma in-licensed China rights to Reoxcare, an IP-protected wound dressing product; Milestone Scientific of the US signed up its own minority-owned JV to market its epidural instrument in China; TWi Biotech was OK'd to begin a Taiwan-US Phase II trial of a novel treatment for gout; BeyondSpring Pharma of the US will start a China-US Phase III trial of its lead drug candidate in lung cancer patients; BioChain announced CFDA approval of Epi proColon®, a diagnostic test for colorectal cancer; and Dan Zhang, CEO of China CRO Fountain Medical Development, discussed the growth drivers of China's drug development sector in an interview. More details.... Stock Symbols: (NYSE: WX) (BSE: 500087) (OTCQB: MLSS) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.